Founded Year
2001Stage
Unattributed | AliveTotal Raised
$20MAbout SanBio
SanBio is a regenerative medicine company with cell-based products in various stages of research, development, and clinical trials. Its proprietary cell-based product, SB623, was built for treatment of chronic motor impairments resulting from stroke.
SanBio Headquarter Location
St. Luke Tower 28F 8-1 Akashi-cho, Chuo-ku
Tokyo, 104-0044,
Japan
Expert Collections containing SanBio
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
SanBio is included in 2 Expert Collections, including Regenerative Medicine.
Regenerative Medicine
1,818 items
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
SanBio Patents
SanBio has filed 43 patents.
The 3 most popular patent topics include:
- Stem cells
- Clusters of differentiation
- Transcription factors
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
2/6/2019 | 4/19/2022 | Transcription factors, Clusters of differentiation, Angiology, Stem cells, Proteins | Grant |
Application Date | 2/6/2019 |
|---|---|
Grant Date | 4/19/2022 |
Title | |
Related Topics | Transcription factors, Clusters of differentiation, Angiology, Stem cells, Proteins |
Status | Grant |
Latest SanBio News
Apr 8, 2022
31-03-2022 Japan’s SanBio Group (TYO: 4592) has announced that SB623 met the primary endpoint and demonstrated a trend toward maintaining the improvement of function and activities of daily living in the final, one-year analysis of the Phase II STEMTRA trial, which evaluated the efficacy and safety of SB623 compared to sham surgery in patients with chronic motor deficit from traumatic brain injury (TBI). These results will be presented in an oral session… This article is accessible to registered users, to continue reading please register for free . A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login . If your trial has come to an end, you can subscribe here. • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. • Daily roundup of key events in pharma and biotech. • Monthly in-depth briefings on Boardroom appointments and M&A news. • Choose from a cost-effective annual package or a flexible monthly subscription. If you are already a registered user please login . The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed Chairman, Sanofi Aventis UK
SanBio Web Traffic
SanBio Rank
When was SanBio founded?
SanBio was founded in 2001.
Where is SanBio's headquarters?
SanBio's headquarters is located at St. Luke Tower 28F, Tokyo.
What is SanBio's latest funding round?
SanBio's latest funding round is Unattributed.
How much did SanBio raise?
SanBio raised a total of $20M.
Who are the investors of SanBio?
Investors of SanBio include CareNet, Medical Incubator Japan and California Institute of Regenerative Medicine.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.